HIGHLIGHTS
- who: Vincenzo Sammartano and collaborators from the Department of Medicine, Surgery and Neuroscience, University of Siena, Azienda Ospedaliero Universitaria Senese, Siena, Italy have published the article: Anti-BCMA novel therapies for multiple myeloma, in the Journal: (JOURNAL)
- how: The KarMMa phase II study was conducted in 128 MM patients who had previously received three or more lines of therapy including a PI an IMiD and an anti-CD38 mAb.
- future: Therapies that target BCMA will play an important role in MM therapy with the ambitious purpose of improving the cure rate however further . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.